MCL1 and cancer: However, it should be noted that in the case of Lin et al., identification of Mcl-1 as a target for sensitizing cancer cells to ABT-737 would not have been possible if siRNAs with partial complementarity to Mcl-1 were not present to downregulate Mcl-1 through “off-target” effects.